Abstract

To learn how plasma fibronectin stabilizes platelet-rich thrombi in injured mesenteric arterioles of mice, we studied the impact of plasma fibronectin on platelet thrombus formation ex vivo in a parallel flow chamber. Thrombi were greater on surfaces coated with fibrin cross-linked to fibronectin by activated factor XIII than on surfaces coated with fibrin lacking cross-linked fibronectin or with fibronectin alone. Platelet thrombi were even greater when plasma fibronectin was perfused with platelets, resulting in deposition of the perfused fibronectin in platelet thrombi. The effect of perfused fibronectin on thrombogenesis was lost if fibronectin deposition was blocked by coperfusion with the N-terminal 70-kDa fragment of fibronectin or a peptide based on the functional upstream domain of protein F1 of Streptococcus pyogenes. Increases in thrombus formation were dependent on a platelet activator such as lysophosphatidic acid, amount of fibronectin cross-linked to fibrin, and concentration of fibronectin in the perfusate. The dependency of fibronectin concentration extended into the range of fibronectin concentrations associated with increased risk of coronary artery disease. At such concentrations, the 2 mechanisms for insolubilization of plasma fibronectin-cross-linking to fibrin and assembly by adherent and aggregating platelets-synergize to result in many-fold enhancement of platelet thrombus formation.

Original languageEnglish
Pages (from-to)3555-3563
Number of pages9
JournalBlood
Volume107
Issue number9
DOIs
StatePublished - May 1 2006

Fingerprint

Dive into the research topics of 'Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi'. Together they form a unique fingerprint.

Cite this